MuScreen™

12 Model Syngeneic Efficacy and PD Mode

Study Site: Crown Bioscience China

6 Model Syngeneic Efficacy and PD Mode

Study Site: Crown Bioscience San Diego

6 Model Tumor Homograft Efficacy Mode

Study Site: Crown Bioscience China

Choose between 6 or 12 well-characterized syngeneic models to evaluate your I/O compound efficacy or PD effect.

* Models are run at our US site in a 6 model MuScreen
^ This line is not applicable for FACS

Syngeneic models display immune heterogeneity and diversity observed in the clinic, enabling comprehensive evaluation of efficacy and PD effects of your immune modulating agents.

Key advantages of syngeneic models include:

• Fully immune competent
• Rapid model establishment
• Availability of historical data

Our syngeneic models are highly characterized, with data including:

• Immune checkpoint inhibitor benchmarking
• Baseline tumor immune profile
• Tumor RNAseq

Visit MuBase^® for all available model data

Learn More

Test your I/O agent antitumor efficacy in vivo on a panel of our unique tumor homograft models

Tumor homografts are transplants of spontaneous or carcinogen-induced GEMM tumors in immunocompetent syngeneic hosts. They preserve the original GEMM tumor molecular and histopathology as well as clinically relevant oncogenic driver mutations.

Our MuPrime tumor homografts have been developed to broaden the number and molecular pathology of preclinical syngeneic models for in vivo pharmacology studies.

Key advantages of MuPrime tumor homografts include:

• Fully immune competent
• Relevant tumor stroma
• Mimic original GEMM tumor molecular and histopathology
• Encompass disease-specific mutations of human cancers
• Similar disease progression as original GEMM tumors

Our tumor homograft models are well characterized with available characterization data including:

• Immune checkpoint inhibitor benchmarking
• Baseline tumor immune profile
• Tumor RNAseq

Visit MuBase for all available model data

Learn More

MuScreen Efficacy and PD Mode are run following a preset schedule along with a shared vehicle group.

The main study endpoint for the efficacy mode is Tumor Growth Inhibition (TGI) with optional terminal Mouse I/O RNA-Seq Panel readout, FACS and IHC.

In the PD mode, choose between FACS analysis of tumor infiltrating lymphocytes and tumor associated macrophages at selected time points, and Mouse I/O RNA-Seq Panel which comprehensively profiles 1080 genes associated with tumor immunity, as your main endpoint. Additional endpoints include cytokine panel profiling in blood and tumor, IHC for biomarker analysis on tumor tissues, blood cells, lymph nodes, and spleen cells.

Frozen or fixed tumors are available on request for both modes.

Find the best models for the preclinical evaluation of your immuno-oncology agent by logging on to Crown Bioscience’s searchable database of well-characterized and validated mouse models. Crown Bioscience offers a wide selection of murine research models including syngeneic, tumor homograft (MuPrime), GEMM, and humanized drug target (HuGEMM) models to screen your compounds of interest.

Access MuBase to explore genomic, molecular, and phenotypic data including tumor growth curves, standard of care response, histopathology data, and immune cell profiling data on this wide collection of immuno-oncology mouse models.

Browse, search, and stratify across different model types

Review treatment data for specific models including immune checkpoint inhibitors

Register Now